Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Licenses Biomarker IP from Johns Hopkins

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen said today that its DxS subsidiary has licensed a biomarker from Johns Hopkins University that it plans to use to develop PCR-based companion diagnostic tests for cancer.

Studies have shown that the PI3K gene that Qiagen licensed has mutations that could serve as predictive biomarkers for the success of some treatments for patients with lung, breast, colorectal, and other cancers.

The patent for the PI3K was filed by Johns Hopkins researchers who were studying tyrosine kinase inhibitors that target the epidermal growth factor receptor pathway, which has been shown to be useful in treating some cancers.

Qiagen already has on the market a PCR-based test using PI3K that is used for research purposes. The firm said that it has a PI3K assay development and partnering program with pharmaceutical companies to develop and market companion diagnostic tests for cancer drug candidates.

Financial terms of the agreement were not released.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.